These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 22149222

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Nanto S, Uematsu M.
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [Abstract] [Full Text] [Related]

  • 4. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis.
    Kawamura Y, Ishii H, Aoyama T, Tanaka M, Takahashi H, Kumada Y, Toriyama T, Murohara T.
    J Vasc Surg; 2009 Nov; 50(5):1057-62. PubMed ID: 19782527
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
    Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Nanto S, Uematsu M.
    JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
    [Abstract] [Full Text] [Related]

  • 8. Gender-related long-term outcome of primary femoropopliteal stent placement for peripheral artery disease.
    Stavroulakis K, Donas KP, Torsello G, Osada N, Schönefeld E.
    J Endovasc Ther; 2015 Feb; 22(1):31-7. PubMed ID: 25775677
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
    Mohr PJ, Oyama JK, Luu JT, Stinis CT.
    Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery.
    Hong SJ, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, Hong MK, Jang Y.
    JACC Cardiovasc Interv; 2015 Mar; 8(3):472-480. PubMed ID: 25703873
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC, Cheng SW, Cheung GC.
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [Abstract] [Full Text] [Related]

  • 15. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis.
    Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, Minar E.
    Radiology; 2004 Aug; 232(2):516-21. PubMed ID: 15286322
    [Abstract] [Full Text] [Related]

  • 16. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions.
    Dohi T, Iida O, Soga Y, Hirano K, Suzuki K, Takahara M, Uematsu M, Nanto S.
    J Vasc Surg; 2014 Apr; 59(4):1009-1015.e1. PubMed ID: 24360237
    [Abstract] [Full Text] [Related]

  • 17. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM, Quérat J, Guyomarch B, Brennan MÁ, Costargent A, Chaillou P, Patra P, Gouëffic Y.
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [Abstract] [Full Text] [Related]

  • 18. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristl R, Schoder M.
    J Am Coll Cardiol; 2013 Oct 08; 62(15):1320-7. PubMed ID: 23831445
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Primary Patency Rate After Nitinol Self-Expandable Stents Implantation in Long, Totally Occluded Femoropopliteal (TASC II C & D) Lesions.
    Elmahdy MF, Buonamici P, Trapani M, Valenti R, Migliorini A, Parodi G, Antoniucci D.
    Heart Lung Circ; 2017 Jun 08; 26(6):604-611. PubMed ID: 27939742
    [Abstract] [Full Text] [Related]

  • 20. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses.
    Iida O, Uematsu M, Soga Y, Hirano K, Suzuki K, Yokoi H, Muramatsu T, Inoue N, Nanto S, Nagata S.
    Catheter Cardiovasc Interv; 2011 Oct 01; 78(4):611-7. PubMed ID: 21805562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.